source
- GSK agrees $1.3 billion deal with Hutchmed for early-stage KRAS-EGFR cancer candidateGSK will pay $110 million upfront to Hutchmed as part of a deal that could reach $1.295 billion, giving GSK worldwide rights to develop and commercialize a preclinical oncology asset. The asset, i…
- Ultragenyx's Angelman gene therapy fails Phase 3, company to cut expensesUltragenyx reported that its late‑stage Aspire trial of apazunersen in Angelman syndrome did not meet its primary or secondary endpoints. The primary goal of improving the Bayley‑4 cognitive raw sc…